SEATTLE, WASH. February 5, 2021 Today the Allen Institute’s Chief Scientific Officer, Todd Peterson, Ph.D., announced plans to step down from his role effective March 1 to pursue other professional opportunities. Peterson joined the Allen Institute in December 2018, in the newly created role of Chief Scientific Officer. In his role he has overseen translational efforts and collaborations and advanced the long-term strategy for all four of the Institute’s divisions. Additionally, Peterson developed and led the Office of Science and Technology, formed the Institute’s Scientific Advisory Board and led the Science and Technology Committee of the Institute’s Board of Directors.
Share this article
Share this article
SEATTLE, Feb. 5, 2021 /PRNewswire/ Today the Allen Institute s Chief Scientific Officer, Todd Peterson, Ph.D., announced plans to step down from his role effective March 1 to pursue other professional opportunities.
Peterson joined the Allen Institute in December 2018, in the newly created role of Chief Scientific Officer. In his role he has overseen translational efforts and collaborations and advanced the long-term strategy for all four of the Institute s divisions. Additionally, Peterson developed and led the Office of Science and Technology, formed the Institute s Scientific Advisory Board and led the Science and Technology Committee of the Institute s Board of Directors.
New Allen Distinguished investigators will tackle unanswered questions about metabolism and the immune system
Awards announced today by The Paul G. Allen Frontiers Group will fund research in health, disease, and technology development all centered on the emerging field of immunometabolism
News provided by
Share this article
Share this article
SEATTLE, Feb. 3, 2021 /PRNewswire/ Just like us, immune cells need fuel to do their jobs. Despite the tight links between human health including our immunity and how our bodies process what we eat, the intersection of immunology and metabolism remains a poorly understood area of human biology.
New awards announced today by The Paul G. Allen Frontiers Group, a division of the Allen Institute, aim to improve that understanding by supporting four research projects in the emerging field of immunometabolism. The projects, which are led by 10 new Allen Distinguished Investigators working in teams of two or three lead investigators per a
Snowy Snowdonia … Rob Piercy’s painting of Tryfan seen from Tal y Braich. All images: Rob Piercy
Snowy Snowdonia … Rob Piercy’s painting of Tryfan seen from Tal y Braich. All images: Rob Piercy
Cut off from the Welsh mountains by lockdown, our Berlin-based writer stays connected through the work of a local artist
PaulScraton
Fri 29 Jan 2021 05.00 EST
Growing up in a small west Lancashire town surrounded by potato and cabbage fields, I always felt the mountains were a long way away. They weren’t of course. Snowdonia was a couple of hours’ drive in one direction. The Lake District was a similar distance in another. An even shorter drive took us across the fields to Formby where, down on the beach when the weather was right, you could even see them – the Welsh hills a line of shadowy shapes on the horizon, across the wide expanse of Liverpool Bay.
Share this article
Share this article
SEATTLE, Jan. 6, 2021 /PRNewswire/ Today, the Allen Institute s founding CEO, Allan Jones, Ph.D., announced he will step down after nearly 18 years with the organization. In 2003, Jones joined the Institute in its planning stages, was promoted the next year to lead the science mission, then became the first Chief Executive Officer in 2010.
Jones will continue to serve as President and CEO until his replacement arrives, at which time he will join the Allen Institute s Board of Directors and will be honored by the title President-Emeritus.
Since the early days of the Allen Institute, Jones partnered with co-founders Paul G. Allen and Jody Allen, as well as the Board of Directors and external science advisors to build one of the most highly respected research institutes, with influence across the globe in brain science, cell science, and immunology. With a focus on impact, and years of pharmaceutical industry experience prior to joining the A